ReviewNature reviews. Gastroenterology & hepatology2011
Vaccinating against Helicobacter pylori infection.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 99 citations in OpenAlex.
- Immunokinetic signatures ofFrontiers in cellular and infection microbiology · 2026Review
- Review
- UnravelingVaccines · 2025Review
- Review
- Intramuscular All-Trans Retinoic Acid-Adjuvanted Nanovaccine Elicits Robust Mucosal and Systemic Immunity AgainstInternational journal of nanomedicine · 2025Article
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- An M cell-targeting recombinant L. lactis vaccine against four H. pylori adhesins.Applied microbiology and biotechnology · 2024Article
- Novel therapeutic regimens againstFrontiers in microbiology · 2024Review
- Copper-Bearing Metal-Organic Framework with Mucus-Penetrating Function for the Multi-Effective Clearance of Mucosal ColonizedResearch (Washington, D.C.) · 2024Article
- Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines.Helicobacter · 2023Article
- Review
- Fructose potentiates the protective efficiency of liveFrontiers in immunology · 2023Article
- Detection and Treatment ofGastroenterology research and practice · 2022Review
- Review
- Vitamin D3 InhibitsFrontiers in cellular and infection microbiology · 2020Article
- Perivascular Lymphocyte Clusters Induced by Gastric Subserous Layer Vaccination Mediate Optimal Immunity against Helicobacter through Facilitating Immune Cell Infiltration and Local Antibody Response.Journal of immunology research · 2020Article
- The frequency of circulating integrin α4β7Helicobacter · 2019Article
- Article
- A mass spectrometry guided approach for the identification of novel vaccine candidates in gram-negative pathogens.Scientific reports · 2019Article
- Review of current diagnostic methods and advances inWorld journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori infection of the gastric mucosa remains a cause of significant morbidity and mortality almost 30 years after its discovery. H. pylori infection can lead to several gastric maladies, including gastric cancer, and although antimicrobial therapies for the infection exist, the cost of treatment for gastric cancer and the prognosis of individuals who present with this disease make vaccine development a cost effective alternative to bacterial eradication. Experimental mucosal and systemic H. pylori vaccines in mice significantly reduce bacterial load and sometimes provide sterilizing immunity. Clinical trials of oral vaccines consisting of H. pylori proteins with bacterial exotoxin adjuvants or live attenuated bacterial vectors expressing H. pylori proteins induce adaptive immune mechanisms but fail to consistently reduce bacterial load. Clinical trials and murine studies demonstrate that where H. pylori is killed, either spontaneously or following vaccination, the host demonstrated cellular immunity. Improved efficacy of vaccines may be achieved in new trials of vaccine formulations that include multiple antigens and use methods to optimize cellular immunity. Unfortunately, the industrial sponsors that served as the primary engine for much of the previous animal and human research have withdrawn their support. A renewed or expanded commitment from the biotechnology or pharmaceutical industry that could exploit recent advances in our understanding of the host immune response to H. pylori is necessary for the advancement of an H. pylori vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.